公开(公告)号：US12121501B2

公开(公告)日：2024-10-22

申请号：US17275581

申请日：2019-09-11

申请人： HOUGH EAR INSTITUTE

发明人： Richard D. Kopke

IPC分类号： A61K31/198 ,  A61K31/15 ,  A61P27/16 ,  A61P41/00

CPC分类号： A61K31/198 ,  A61K31/15 ,  A61P27/16 ,  A61P41/00

摘要： Disclosed here is a method of alleviating negative effects of cochlear implant surgery in a subject in need thereof comprising administering effective amounts of 2,4-disulfonyl α-phenyl tertiary butyl nitrone (2,4-DSPBN) or a pharmaceutically acceptable salt thereof and N-acetylcysteine (NAC) or a pharmaceutically acceptable salt thereof to a subject prior to, during, and/or after undergoing cochlear implant surgery.

公开(公告)号：US20240307377A1

公开(公告)日：2024-09-19

申请号：US18670599

申请日：2024-05-21

申请人： Alto Neuroscience, Inc.

发明人： Amit ETKIN ,  Dan SEGAL ,  Wei WU ,  Li SHEN ,  Vinit SHAH ,  Adam SAVITZ

IPC分类号： A61K31/496 ,  A61K9/00 ,  A61K31/138 ,  A61K31/15 ,  A61K31/165 ,  A61K31/343 ,  A61K31/36 ,  A61K31/381 ,  A61P25/24

CPC分类号： A61K31/496 ,  A61K9/0053 ,  A61K31/138 ,  A61K31/15 ,  A61K31/165 ,  A61K31/343 ,  A61K31/36 ,  A61K31/381 ,  A61P25/24

摘要： This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, posttraumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms), in a patient who is cognitively impaired or has poor or slow cognition or difficulty making decisions or exhibits certain EEG properties. The present invention also relates to the selection of patients with a biomarker (e.g., EEG) and/or clinical symptoms who would most benefit from such compounds.

公开(公告)号：US20240307303A1

公开(公告)日：2024-09-19

申请号：US18675464

申请日：2024-05-28

申请人： RXOS Medical Inc.

发明人： Richard M. Millis ,  Jeffrey A. Niezgoda ,  Rajagopalan Sridhar

IPC分类号： A61K9/06 ,  A61K9/00 ,  A61K31/13 ,  A61K31/15 ,  A61K31/216 ,  A61K31/445 ,  A61K33/38 ,  A61K45/06 ,  A61K47/32 ,  A61L15/32 ,  A61L15/44 ,  A61L15/60

CPC分类号： A61K9/06 ,  A61K9/0014 ,  A61K31/13 ,  A61K31/15 ,  A61K31/216 ,  A61K31/445 ,  A61K33/38 ,  A61K45/06 ,  A61K47/32 ,  A61L15/325 ,  A61L15/44 ,  A61L15/60

摘要： A polyfunctional radical scavenger hydrogel formulation providing extended protection of the extracellular space within a wound site. The polyfunctional radical scavenger hydrogel formulation is generally formed from a hydrogel, a first radical scavenger and a second radical scavenger differing from the first radical scavenger with respect to at least one property. A portion of the first radical scavenger included with the formation and/or second radical scavenger included within the formulation may be dissolved, suspended and/or bonded to a polymer of the hydrogel.

公开(公告)号：US20240226035A1

公开(公告)日：2024-07-11

申请号：US18559087

申请日：2022-05-04

申请人： UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH

发明人： O'Bryant Sid E.

IPC分类号： A61K31/137 ,  A61K31/015 ,  A61K31/07 ,  A61K31/095 ,  A61K31/122 ,  A61K31/135 ,  A61K31/138 ,  A61K31/15 ,  A61K31/194 ,  A61K31/352 ,  A61K31/375 ,  A61K31/4045 ,  A61K31/42 ,  A61K31/421 ,  A61K31/4985 ,  A61K31/50 ,  A61K31/5375 ,  A61K33/00 ,  A61K33/04 ,  A61K38/06 ,  G16B25/10 ,  G16B40/20

CPC分类号： A61K31/137 ,  A61K31/015 ,  A61K31/07 ,  A61K31/095 ,  A61K31/122 ,  A61K31/135 ,  A61K31/138 ,  A61K31/15 ,  A61K31/194 ,  A61K31/352 ,  A61K31/375 ,  A61K31/4045 ,  A61K31/42 ,  A61K31/421 ,  A61K31/4985 ,  A61K31/50 ,  A61K31/5375 ,  A61K33/00 ,  A61K33/04 ,  A61K38/063 ,  G16B25/10 ,  G16B40/20

摘要： The present invention includes a method for selecting a subject for a targeted treatment for Parkinson's Disease, the method comprising: obtaining or having obtained a sample from the subject; measuring in the blood or serum sample the expression level of one or more first biomarkers; comparing the level of expression of the one or more first biomarkers from the subject's sample with the expression level of a corresponding one or more first biomarkers from a statistical sample representative of biomarkers in a normal subject; and if the subject is found to have a statistically different expression level of the one or more biomarkers when compared to the expression level of the corresponding one or more biomarkers from the statistical sample, treating the subject with a monoamine oxidase inhibitor, an antioxidant, or both.

公开(公告)号：US12023339B2

公开(公告)日：2024-07-02

申请号：US17508729

申请日：2021-10-22

申请人： AF Chemicals, LLC

发明人： Michael Kelner

IPC分类号： A61K31/5375 ,  A61K31/047 ,  A61K31/121 ,  A61K31/122 ,  A61K31/135 ,  A61K31/15 ,  A61K31/16 ,  A61K31/18 ,  A61K31/192 ,  A61K31/198 ,  A61K31/351 ,  A61K31/357 ,  A61K31/401 ,  C12Q1/6886

CPC分类号： A61K31/5375 ,  A61K31/047 ,  A61K31/121 ,  A61K31/122 ,  A61K31/135 ,  A61K31/15 ,  A61K31/16 ,  A61K31/18 ,  A61K31/192 ,  A61K31/198 ,  A61K31/351 ,  A61K31/357 ,  A61K31/401 ,  C12Q1/6886 ,  C12Q2600/158 ,  C12Q2600/16

摘要： In an embodiment of the invention, a method of treating cancer includes screening to select a patient population that will respond to an Illudofulvene Analog composition based on the presence of one or more Transcription Coupled Repair (TCR) mutations, deletions or other events interfering with TCR biomarker expression in combination with upregulation of Myc and/or PTGR biomarker expression and treating the patient population with the Illudofulvene Analog composition.

公开(公告)号：US20240199630A1

公开(公告)日：2024-06-20

申请号：US18551912

申请日：2022-03-23

申请人： FUNDACIÓN DEL SECTOR PÚBLICO ESTATAL CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS

发明人： Joaquín PASTOR FERNÁNDEZ ,  Sonia MARTÍNEZ GONZÁLEZ ,  Carmen BLANCO APARICIO ,  Ana Belén GARCÍA GARCÍA ,  Sonsoles RODRÍGUEZ ARÍSTEGUI ,  Cristina Ana GÓMEZ DE LA OLIVA ,  María Isabel ALBARRÁN SANTIÑO ,  Antonio CEBRIÁ GÓMEZ ,  Marcos MALUMBRES MARTÍNEZ

IPC分类号： C07D491/147 ,  A61K31/145 ,  A61K31/15 ,  A61K31/4375 ,  A61K31/4439 ,  A61K31/50 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/55 ,  A61K31/566 ,  A61K31/635 ,  C07D498/14

CPC分类号： C07D491/147 ,  A61K31/145 ,  A61K31/15 ,  A61K31/4375 ,  A61K31/4439 ,  A61K31/50 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/55 ,  A61K31/566 ,  A61K31/635 ,  C07D498/14

摘要： The present invention relates to a group of compounds with a tricyclic core based on imidazo[1,2-b]pyridazine of formula (I):




which are inhibitors of HASPIN, whose activity is required for the proliferation of certain tumoral cells, so the compounds of the invention are useful for the prevention and/or treatment of cancer, alone or in combination with chemotherapeutic agents.

公开(公告)号：US20240156775A1

公开(公告)日：2024-05-16

申请号：US18416748

申请日：2024-01-18

申请人： Vanda Pharmaceuticals Inc.

发明人： Marlene Michelle Dressman ,  Louis William Licamele ,  Mihael H. Polymeropoulos

IPC分类号： A61K31/343 ,  A61K9/00 ,  A61K31/00 ,  A61K31/15 ,  A61K31/277 ,  A61K31/496 ,  A61K45/06 ,  A61P25/20 ,  G01N30/72 ,  G01N33/68 ,  G01N33/74 ,  G16H50/20

CPC分类号： A61K31/343 ,  A61K9/0053 ,  A61K9/006 ,  A61K31/00 ,  A61K31/15 ,  A61K31/277 ,  A61K31/496 ,  A61K45/06 ,  A61P25/20 ,  G01N30/7233 ,  G01N33/6893 ,  G01N33/74 ,  G16H50/20 ,  G01N2800/2864

摘要： Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

公开(公告)号：US11980651B1

公开(公告)日：2024-05-14

申请号：US18339152

申请日：2023-06-21

申请人： Transdermal Biotechnology, Inc.

发明人： Nicholas V. Perricone

IPC分类号： A61K38/04 ,  A61K9/00 ,  A61K31/15 ,  A61K31/385 ,  A61K31/675 ,  A61K31/685 ,  A61K38/10

CPC分类号： A61K38/04 ,  A61K9/0014 ,  A61K9/0046 ,  A61K31/15 ,  A61K31/385 ,  A61K31/675 ,  A61K31/685 ,  A61K38/10

摘要： The present disclosure generally relates to compositions comprising dihexa and methods for making or using said compositions. In some aspects, the compositions disclosed herein may comprise one or more additional active ingredients, including lipoic acid, spadin peptide, and/or phenyl-N-tert-butylnitrone. Compositions such as these may be used in certain embodiments, for example, to enhances a subject's hearing or to treat a hearing disorder, etc. In some embodiments, the compositions are topical compositions configured to treat hearing loss via administration, e.g., to the skin behind the outer ear or directly to the eardrum of a subject, etc. In some cases, the compositions disclosed herein may comprise one or more excipients to aid in transdermal delivery. For instance, in certain embodiments, the compositions comprise lecithin and/or other components that may facilitate delivery through the skin. Other aspects are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

公开(公告)号：US11834401B2

公开(公告)日：2023-12-05

申请号：US16921318

申请日：2020-07-06

申请人： THE JOHNS HOPKINS UNIVERSITY

发明人： Douglas Robinson ,  Alexandra Surcel ,  Win Pin Ng ,  Caren L. Freel Meyers

IPC分类号： C07C49/825 ,  A61P35/00 ,  A61K31/12 ,  A61K31/136 ,  A61K31/15 ,  A61K31/27 ,  A61K45/06 ,  C07C271/58 ,  C07C275/30 ,  C12Q1/25 ,  C12Q1/02 ,  C07C251/80

CPC分类号： C07C49/825 ,  A61K31/12 ,  A61K31/136 ,  A61K31/15 ,  A61K31/27 ,  A61K45/06 ,  A61P35/00 ,  C07C251/80 ,  C07C271/58 ,  C07C275/30 ,  C12Q1/025 ,  G01N2333/44 ,  G01N2333/4712 ,  G01N2500/10 ,  A61K31/136 ,  A61K2300/00 ,  A61K31/12 ,  A61K2300/00 ,  A61K31/15 ,  A61K2300/00 ,  A61K31/27 ,  A61K2300/00

摘要： Described are methods of treating or preventing a disease in a subject treatable by modulating cell mechanics. The method includes administering to a subject having or at risk for such a disease a pharmaceutical composition. comprising an agent selected from the group comprising a salt, solvate, or stereoisomer of compound (VIII) or its derivatives or a mixture of their constituents, where the compound has the formula:

公开(公告)号：US11833130B2

公开(公告)日：2023-12-05

申请号：US17206811

申请日：2021-03-19

申请人： Vanda Pharmaceuticals Inc.

发明人： Marlene Michelle Dressman ,  John Joseph Feeney ,  Louis William Licamele ,  Mihael H. Polymeropoulos

IPC分类号： A61K31/343 ,  A61K31/00 ,  A61K45/06 ,  A61K31/15 ,  A61K31/277 ,  A61K31/496 ,  G01N30/72 ,  G16H50/20 ,  G01N33/74 ,  G01N33/68 ,  A61K9/00

CPC分类号： A61K31/343 ,  A61K9/006 ,  A61K9/0053 ,  A61K31/00 ,  A61K31/15 ,  A61K31/277 ,  A61K31/496 ,  A61K45/06 ,  G01N30/7233 ,  G01N33/6893 ,  G01N33/74 ,  G16H50/20 ,  G01N2800/2864 ,  A61K31/343 ,  A61K2300/00 ,  A61K31/15 ,  A61K2300/00 ,  A61K31/277 ,  A61K2300/00 ,  A61K31/496 ,  A61K2300/00

摘要： Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.